Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00394186 | A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS) | PHASE2 | COMPLETED | 100 | — | — | Aug 1, 2006 | - | May 18, 2009 | 19 | Australia, France +1 |
| Name | Type | Description |
|---|---|---|
| GW427353 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: \- Diagnosis of IBS which meets the Rome II criteria, screening pain score to be \> 1.5 (0= no pain, 4 = very severe pain) Exclusion Criteria: * Subjects not meeting the Rome II criteria for the diagnosis of IBS * Subjects with no stool for 7 days during the screen
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Ardelyx, Inc. | ARDX | 4 | PHASE3 | Tenapanor |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Eluxadoline |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | — | Undisclosed |
| Johnson & Johnson | JNJ | 1 | — | Anti TNF therapy including infliximab, No Biologics |
| Cooper Companies, Inc. | COO | 1 | NA | Undisclosed |